Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Skin fibrosis is a dermal lesion associated with inflammatory factors. However, the exact causal relationship between circulating inflammatory proteins (CIPs) and skin fibrosis remains unclear. To investigate this potential association and mediated effect, Mendelian randomization (MR) and two-step MR were used.
Methods: Summary statistics from genome-wide association studies (GWAS) were extracted from the GWAS Catalog for CIPs, blood metabolites (BMs), and skin fibrosis. Two-sample MR and reverse MR were conducted to determine the effect of CIPs on skin fibrosis. Two-step MR was then performed to investigate the role of BMs in mediating the effect of CIPs on skin fibrosis. Reverse MR analysis was performed to confirm the unidirectional causality between CIPs and BMs, as well as between BMs and skin fibrosis.
Results: Bidirectional Mendelian randomization revealed negative associations between skin fibrosis and the levels of T-cell surface glycoprotein CD6 isoform (odds ratio [OR] 0.670 [95% confidence interval [CI] 0.472, 0.951], = 0.025), Delta and Notch-like epidermal growth factor-related receptor (OR 0.779 [95% CI 0.609, 0.998], = 0.048), and Interleukin-10 receptor subunit beta (OR 0.541 [95% CI 0.332, 0.884], = 0.014). There was a positive association between skin fibrosis and levels of Fibroblast growth factor 21 (OR 2.276 [95% CI 1.064, 4.870], = 0.034). Two-step MR showed that Retinol (Vitamin A) to the linoleoyl-arachidonoyl-glycerol ratio (β 0.108 [95% CI 0.006, 0.210], = 0.004) and the Cholesterol to linoleoyl-arachidonoyl-glycerol ratio (β 0.238 [95% CI 0.002, 0.474], = 0.048) were identified as mediators, which showed evidence of the mediated effect of the levels of Fibroblast growth factor 21 on Keloid through these mediators.
Conclusion: The study presented credible evidence of a causal association between CIPs and skin fibrosis, with BMs potentially acting as a mediator in this association. These findings offer new insights into early screening and prevention of skin fibrosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958232 | PMC |
| http://dx.doi.org/10.3389/fendo.2025.1416993 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Formation of actin mesh structures and alpha-smooth muscle actin dynamics in fibroblasts contribute to dermal regeneration in mouse fetus.
PLoS One
September 2025
Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo, Japan.
In adult mammals and other highly developed animals, incomplete wound healing, scar formation, and fibrosis occur. No treatment for complete tissue regeneration is currently available. However, in mice, at up to 13 days of gestation, early embryonic wounds regenerate without visible scarring.
View Article and Find Full Text PDFBaricitinib Combination Therapy Demonstrates Significant Improvement in Cardiac Conduction Defects in Rapidly Progressive Systemic Sclerosis: A Case Report.
Open Access Rheumatol
August 2025
Department of Rheumatology and Immunology, the First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China.
Objective: To evaluate the efficacy of baricitinib in combination therapy for managing refractory, rapidly progressive systemic sclerosis (SSc) with severe cardiac conduction defects and interstitial lung disease (ILD).
Methods: A 48-year-old male patient with SSc complicated by significant cardiac enlargement, third-degree atrioventricular block, heart failure, progressive ILD, and partial intestinal obstruction was included in the study. Prior treatments with mycophenolate mofetil (MMF), tacrolimus, and cyclophosphamide (CTX) had shown limited efficacy.
The Trilogy of Skin Regeneration via Metal-Organic Frameworks Nanomedicine: Precision Management of Refractory Wounds, Pathological Scarring, and Hair Follicle Reactivation.
Int J Nanomedicine
September 2025
Department of Plastic Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, People's Republic of China.
Diabetic infected wounds represent a formidable clinical challenge characterized by persistent hyperglycemia-induced pathological cascades that disrupt normal healing processes through multiple mechanisms including chronic inflammation, oxidative stress, and microvascular dysfunction. As prototypical chronic wounds, they exhibit severely impaired tissue regeneration due to this multifaceted dysfunction in both skin architecture and biological function. Metal-organic frameworks (MOFs) have emerged as promising next-generation therapeutic platforms owing to their exceptional structural tunability, multifunctional properties, and precise spatiotemporal drug delivery capabilities.
View Article and Find Full Text PDFOverlapping Connective Tissue Disease-Polymyositis and Diffuse Systemic Scleroderma: A Case Report.
Clin Med Insights Arthritis Musculoskelet Disord
September 2025
Department of Surgery, University of Arkansas for Medical Sciences, Fayetteville, AR, USA.
Polymyositis with concomitant scleroderma is a rare, progressive condition with profound consequences if not addressed promptly. Severity and symptom presentation varies between patients, and much is unknown about how best to treat overlapping connective tissue diseases. This case discusses the rare presentation, medical evaluation, and successful treatment of a 46-year-old woman with excessive muscle atrophy, weakness, and tissue fibrosis, who was diagnosed with overlapping connective tissue disorder after extensive work up that included a muscle biopsy, skin punch biopsy, and autoantibody lab work.
View Article and Find Full Text PDFDipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects.
Front Pharmacol
August 2025
Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Dipeptidyl peptidase 1 (DPP1) inhibitors constitute a major advance in respiratory disease therapeutics. Through selective blockade of neutrophil serine protease (NSP) activation, these agents establish novel treatment paradigms for inflammatory respiratory conditions characterized by neutrophil-driven pathology. This comprehensive review examines the development status, clinical efficacy, and safety profile of DPP1 inhibitors in neutrophil-driven diseases, particularly non-cystic fibrosis bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD).
View Article and Find Full Text PDF